Effect of Protein Quality During Overreaching in Trained Cyclists
Monitoring Exercise Performance and Mitigating Training Stress in Endurance-trained Cyclists
1 other identifier
interventional
11
1 country
1
Brief Summary
Athletes frequently undertake periods of intensified training commonly referred to as "overreaching." These training periods acutely decrease performance, with the expectation that performance will rebound and improve after a short recovery. Yet, overreaching does not always improve performance and may be a precursor to overtraining syndrome, a long-term decrement in performance. A nutritional intervention focused on the adoption of 'best practices' for protein feeding (optimal timing, dose, and quality) could help reduce the stress of overreaching, reduce the likelihood of developing overtraining syndrome, and augment adaptations to intensified exercise. While the nutrition study is our main interest, the investigators first want to validate the measurement of exercise performance. Accordingly, this project consists of two related studies: (1) the assessment of short time trials for reliability and validity; and (2) the assessment of optimal protein feeding to decrease the stress of overreaching and improve outcomes following training.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2017
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2018
CompletedFirst Submitted
Initial submission to the registry
June 19, 2019
CompletedFirst Posted
Study publicly available on registry
June 21, 2019
CompletedJune 21, 2019
June 1, 2019
5 months
June 19, 2019
June 20, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Rate of myofibrillar muscle protein synthesis
Rate of myofibrillar and protein synthesis (%/day)
12 days
Rate of Sarcoplasmic muscle protein synthesis
Rate of sarcoplasmic muscle protein synthesis (%/day)
12 days
Secondary Outcomes (5)
Plasma amino acids
1 x 1 hour
Sleep efficiency (%)
12 days
Sleep fragmentation
12 days
Wake after sleep onset (WASO) in minutes
12 days
Total sleep time (min)
12 days
Study Arms (2)
Alpha-lactalbumin
EXPERIMENTALParticipants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
Collagen peptides
ACTIVE COMPARATORParticipants will consume 60 g of collagen peptides for 3 training days.
Interventions
A protein fraction of whey protein, higher in tryptophan
Eligibility Criteria
You may qualify if:
- non-smokers
- non-diabetic
- Participants had to be training regularly (performing aerobic exercise at least 4 times per week, including regular cycling exercise)
- Generally healthy
You may not qualify if:
- consuming excessive alcohol (\>21 units per week)
- use of an investigational drug or nutraceutical in the previous 30 days
- dairy allergy
- history of significant loss or gain of body mass in the past 6 months (\>2kg)
- regular use of non-steroidal anti-inflammatory drugs
- infectious disease, and/or the presence of any relevant disease (e.g., gastrointestinal, cardiovascular, neuromuscular, etc.).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ivor Wynne Centre
Hamilton, Ontario, L8S 4L8, Canada
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stuart Phillips, PhD
McMaster University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Participants and the investigators will be blinded the the supplement type, only the LPI will have the codes to decipher the supplement type. Supplements are referred to as A and B.
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 19, 2019
First Posted
June 21, 2019
Study Start
November 1, 2017
Primary Completion
April 1, 2018
Study Completion
August 30, 2018
Last Updated
June 21, 2019
Record last verified: 2019-06
Data Sharing
- IPD Sharing
- Will not share